JAK2 and myeloproliferative neoplasm: Recently, Mullally et al. [41], using a JAK2V617F knock-in mouse MPN model, have shown that JAK2 inhibitors are able to control the hyperproliferation of committed hematopoietic progenitors in MPN, but are unable to eliminate the cell population from which the initiator clone arises.